Malaysian Genomics Resource Centre Berhad Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Malaysian Genomics Resource Centre Berhad.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	27.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is Now An Opportune Moment To Examine Malaysian Genomics Resource Centre Berhad (KLSE:MGRC)?

Mar 02

We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth

Feb 15

Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth

Nov 02

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Malaysian Genomics Resource Centre Berhad no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

KLSE:MGRC - Estimaciones futuras de los analistas y datos financieros pasados (MYR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	10	-8	N/A	N/A	N/A
3/31/2024	11	-18	N/A	N/A	N/A
12/31/2023	10	-19	-17	-17	N/A
6/30/2023	8	-14	-23	-22	N/A
3/31/2023	12	1	-21	-20	N/A
12/31/2022	17	6	-20	-19	N/A
9/30/2022	23	8	-11	-9	N/A
6/30/2022	28	7	-1	0	N/A
3/31/2022	22	1	-3	2	N/A
12/31/2021	19	-1	-6	-1	N/A
9/30/2021	11	-3	-9	-5	N/A
6/30/2021	2	-4	-7	-3	N/A
3/31/2021	-3	-31	12	14	N/A
12/31/2020	-4	-33	13	16	N/A
9/30/2020	1	-7	10	13	N/A
6/30/2020	1	-6	9	12	N/A
3/31/2020	5	20	-7	-7	N/A
12/31/2019	5	21	-7	-7	N/A
9/30/2019	0	-5	-3	-2	N/A
6/30/2019	0	-5	-3	-1	N/A
3/31/2019	7	-4	-6	-4	N/A
12/31/2018	13	-5	-7	-4	N/A
9/30/2018	20	-5	-7	-5	N/A
6/30/2018	26	-5	-7	-6	N/A
3/31/2018	23	-3	N/A	1	N/A
12/31/2017	18	-1	N/A	4	N/A
9/30/2017	13	-1	N/A	4	N/A
6/30/2017	10	1	N/A	4	N/A
3/31/2017	9	0	N/A	3	N/A
12/31/2016	9	1	N/A	1	N/A
9/30/2016	10	2	N/A	3	N/A
6/30/2016	10	2	N/A	4	N/A
3/31/2016	12	2	N/A	0	N/A
12/31/2015	14	3	N/A	-1	N/A
9/30/2015	15	4	N/A	1	N/A
6/30/2015	14	4	N/A	0	N/A
3/31/2015	13	3	N/A	1	N/A
12/31/2014	9	0	N/A	2	N/A
9/30/2014	6	-2	N/A	-2	N/A
6/30/2014	4	-4	N/A	-3	N/A
3/31/2014	3	-6	N/A	-4	N/A
12/31/2013	2	-6	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de MGRC es superior a la tasa de ahorro (3.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de MGRC crezcan más rápidamente que el mercado MY

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de MGRC crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de MGRC crezcan más rápidamente que el mercado de MY.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de MGRC crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MGRC se prevé que sea elevada dentro de 3 años.

Malaysian Genomics Resource Centre Berhad Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates fall by 33%

Price target decreased by 13% to RM0.95

Recent updates

New major risk - Market cap size

Malaysian Genomics Resource Centre Berhad Appoints Yap Kok Wei as Independent and Non Executive Director

New major risk - Revenue and earnings growth

Malaysian Genomics Resource Centre Berhad, Annual General Meeting, Apr 29, 2024

Malaysian Genomics Resource Centre Berhad, Annual General Meeting, Apr 29, 2024

Malaysian Genomics Resource Centre Berhad Announces Redesignation of Encik Muhammad Badri Bin Hussin to Chief Operating Officer from Director

Full year 2023 earnings: EPS and revenues miss analyst expectations

Malaysian Genomics Resource Centre Berhad Announces Update on Material Litigation

Malaysian Genomics Resource Centre Berhad Appoints Mohammad Hasni Bin Ibrahim as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Appoints Datuk Wira Muhammad Faizal Bin Zainol as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Announces Re-Designation of Aswath A/L Ramakrishnan as A Non-Audit and Risk Management Committee Member

Malaysian Genomics Resource Centre Berhad Provides Material Litigation Update

Malaysian Genomics Resource Centre Berhad Appoints Encik Muhammad Badri Bin Hussin, Age 50, as Member of Audit Committee, Date of Change 25 Oct 2023

Malaysian Genomics Resource Centre Berhad Announces Appointment of Encik Muhammad Badri Bin Hussin as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Announces Appointment of Encik Mohamad Ruzaini Bin Hamzah as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Announces Resignation of Encik Sasha Omar Firdaus Bin Aamir Nordin as Chief Executive Officer

Full year 2023 earnings released: RM0.11 loss per share (vs RM0.059 profit in FY 2022)

Malaysian Genomics Resource Centre Berhad Announces Resignation of Aswath A/L Ramakrishnan as Independent and Non Executive Member of Nomination and Remuneration Committee

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad Appoints Miss Chih Yi May as Independent and Non Executive Director effective June 1, 2023

High number of new and inexperienced directors

Consensus revenue estimates fall by 33%

Malaysian Genomics Resource Centre Berhad Appoints Encik Syed Zulkifli Bin Syed Ismail as Independent and Non Executive Member of Nomination and Remuneration Committee

Third quarter 2023 earnings released: RM0.022 loss per share (vs RM0.016 profit in 3Q 2022)

Malaysian Genomics Resource Centre Berhad Re-designates Encik Mohd Shakir Bin Shahimi to Chairman of Audit Committee

Malaysian Genomics Resource Centre Berhad Appoints Mr. Aswath A/L Ramakrishnan as Independent and Non Executive Director

Is Now An Opportune Moment To Examine Malaysian Genomics Resource Centre Berhad (KLSE:MGRC)?

Price target decreased by 13% to RM0.95

Second quarter 2023 earnings released: RM0.01 loss per share (vs RM0.008 profit in 2Q 2022)

First quarter 2023 earnings released: EPS: RM0.007 (vs RM0.002 in 1Q 2022)

Malaysian Genomics Resource Centre Berhad Announces the Re-Designation of Encik Mohd Shakir Bin Shahimi from Member of Nomination and Remuneration Committee to Chairman of Nomination and Remuneration Committee

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad Announces Resignation of Teoh Ai Ling as Principal Officer

Full year 2022 earnings released: EPS: RM0.059 (vs RM0.04 loss in FY 2021)

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: RM0.059 (vs RM0.04 loss in FY 2021)

Malaysian Genomics Resource Centre Berhad Appoints Encik Mohd Shakir Bin Shahimi as Member of Nomination and Remuneration Committee

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad announces redesignation of Dato' Seri Dr. Chen Chaw Min from Independent Director to Independent and Non Executive Chairman

Others Malaysian Genomics Announces Board Changes

Malaysian Genomics Resource Centre Berhad Appoints Ku Chong Hong, Designation Chairman of Nomination and Remuneration Committee Directorate Independent and Non Executive, Date of Change 13 Jul 2022

Third quarter 2022 earnings released: EPS: RM0.016 (vs RM0.002 in 3Q 2021)

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad Announces the Launch of Its Genetic Screening Plus Personalised Health Supplements Solutions on the Airasia Super App

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Malaysian Genomics Resource Centre Berhad Announces Re-Designation of Encik Noor Azri Bin Dato' Sri Noor Azerai as Independent Executive Director

We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth

High number of new and inexperienced directors

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new directors

Financial Controller Sek Cheah has left the company

Senior Independent Non-Executive Chairman Rafiah Salim has left the company

Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth

Full year 2021 earnings released: RM0.04 loss per share (vs RM0.062 loss in FY 2020)

High number of new directors

New 90-day high: RM1.22

New 90-day high: RM1.18

New 90-day high: RM1.11

New 90-day high: RM0.80

Malaysian Genomics Resource Centre Berhad Renames the Audit Committee as Audit and Risk Management Committee

First quarter 2021 earnings released: RM0.008 loss per share

New 90-day high: RM0.64

Malaysian Genomics Resource Centre Berhad Announces Appointment of ENCIK SASHA OMAR FIRDAUS BIN AAMIR NORDIN as Chief Executive Officer

New 90-day high - RM0.53

Malaysian Genomics Resource Centre Berhad Announces Resignation of Encik Robert George Hercus @ Abdul Karim Hercus as Executive Managing Director

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento